FIG. 1.

Photomicrographs of lungs stained to detect βgal (A to D) or alkaline phosphatase (E to G). Ad.RSV-βgal was administered intratracheally on day 0 to control mice (A and C) or mice treated with the combined regimen (B and D), and βgal expression was assessed 7 (A and B) or 28 (C and D) days after vector administration. For treatment details, see Materials and Methods. Ad.CMV-AlkPhos was administered intratracheally at 90 to 102 days after primary vector administration to control mice (E), mice treated with the combined regimen at the time of primary vector administration (F) or mice receiving Ad.CMV-AlkPhos as primary vector (G), and alkaline phosphatase expression was assessed 3 to 4 days later. For the representative animals shown, the scores (see Materials and Methods and Fig. 2) for airway and alveolar expression of βgal were, respectively, 0.9 and 0.6 (A), 1.8 and 1.9 (B), 0.0 and 0.0 (C), and 1.5 and 2.6 (D) and for alkaline phosphatase, respectively, 1.6 and 1.5 (E), 1.6 and 1.7 (F), and 0.0 and 0.0 (G).